A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)

Launched by MERCK SHARP & DOHME LLC · Oct 15, 2024

Keywords

ClinConnect Summary

This clinical trial, called MK-1708-005, is studying a new medication called MK-1708 to see if it is safe and how well it is tolerated by healthy elderly participants. The researchers want to understand how the body processes this medication over time and whether it stays at a safe level in the blood after 24 hours. The trial is currently looking for older adults within the age range of 65 to 75 who are generally in good health and have a body mass index (BMI) between 18 and 32.

Participants in this study can expect to undergo some tests to confirm their health status and may receive different doses of MK-1708 to find out what works best. It's important to note that individuals with certain medical histories, such as significant health issues or a history of cancer, may not be eligible to participate. This study aims to gather valuable information that could help improve treatments for elderly patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The key inclusion criteria include but are not limited to the following:
• • Is in good health before randomization
• • Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive
• Exclusion Criteria:
• The key exclusion criteria include but are not limited to the following:
• • Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• • Has a history of cancer (malignancy). Participants with definitively treated disease who, in the opinion of the study investigator, are highly unlikely to have a recurrence for the duration of the study may be enrolled at the discretion of the investigator